Skip to main
IDXX

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories (IDXX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

IDEXX Laboratories maintains a strong customer retention rate of approximately 97%, which enhances the predictability of its revenue and earnings streams. The company has also demonstrated robust organic consumables recurring revenue growth, achieving a compound annual growth rate (CAGR) of approximately 16% from 2016 to 2022. With expectations of expanding clinical visits and compelling growth benefits tied to its complete suite of offerings, IDEXX is well-positioned to capitalize on a potential recovery in pet patient visits and overall market growth.

Bears say

IDEXX Laboratories has experienced a consistent decline in clinical vet visits, with a reported decrease of -1.7% year-over-year in Q4'25, reflecting a worsening trend since Q2'25's decline of -2.2%. This ongoing reduction in vet visits is anticipated to adversely impact the adoption rate of IDEXX's diagnostic products, creating potential headwinds for growth in a market increasingly sensitive to economic conditions, particularly among lower-income pet owners. Additionally, the broader economic challenges could lead to cash flow issues for both customers and suppliers, further diminishing demand for IDEXX's offerings and increasing the risk of revenue slowdown.

IDEXX Laboratories (IDXX) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IDEXX Laboratories (IDXX) Forecast

Analysts have given IDEXX Laboratories (IDXX) a Buy based on their latest research and market trends.

According to 9 analysts, IDEXX Laboratories (IDXX) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $731.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $731.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IDEXX Laboratories (IDXX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.